Ricoh Company, Ltd.

Canon Kabushiki Kaisha

Kowa Company Limited

Kyocera Corporation

Omron Corporation

The University of Electro-communications

Campus Create Co., Ltd.

Satoshi Kojima

Tsuneyasu Nagatomo

Osamu Uchinokura

Junichi Awamura

Satoshi Takahashi

Daisuke Inoue

Daisuke Ito

Hiroki Kobayashi

Satoshi Ogawa

Yoshihiro Moriya

Shin Hasegawa

Ryuji Okamura

Shingo Sakashita

Hitoshi Murayama

Makoto Aoki

Takayuki Shimizu

Naohiro Watanabe

Toyoshi Sawada

Junichiro Hashizume

Toshiyuki Ehara

Tomomi Suzuki

Takahiro Honda

Tsuyoshi Sugimoto

Ryota Inoue

Yasuyoshi Takai

Kazuyoshi Akiyama

Hiroshi Hosokawa

Takuya Seshita

Masafumi Sano

Masaki Watanabe

Kenji Kikuchi

Ryo Hayashi

Keishi Saito

Hideki Sugiura

Yohta Sakon

Shinji Tamaki

Yasuaki Iwamoto

Kazuhiko Takada

Fumihiro Sasaki

Yuta Nakamura

Shunji Katoh

Tetsuya Takei

Kazuto Hosoi

Hiroaki Niino

Tatsuki Yamaguchi

Yuuki Matsushita

Shinji Tsuchida

Teruki Kusahara

Tomoki Murayama

Koji Hitsuishi

Yukiko Ishijima

Hideaki Matsuoka

Hirokazu Ohtoshi

Masahiko Ishikawa

Jun Ohira

Syouko Satoh

Hironori Owaki

Hironori Ohwaki

Tatsuru Moritani

Mamoru Hozumi

Masaya Fukuda

Shosuke Aoai

Motoya Yamada

Masaaki Yamamura

Naohito Shimota

Masayuki Koyano

Masahiro Ohmori

Hiroshi Ikeguchi

Hiroki Hagiwara

Michiharu Suzuki

Yuta Nagata

Daisuke Asahina

Masanobu Gondoh

Hiroyuki Katagiri

Kaori Toyama

Yasuo Muneta

Masana Shiba

Shohei Gohda

Hyo Shu

Yukihiro Abe

Rintaro Takahashi

Mio Kumai

Kiminori Masuda

Hirokazu Otoshi

Kotaro Okamura

Daisuke Tazawa

Yuka Aoyama

Azumi Miyaake

Amika Sagara

Masahiko Tonogaki

Ryo Miyakoshi

Ayano Momose

Yutaka Tahara

Minoru Oka

Kazunari Ooyama

An active energy ray curing composition contains a polymerizable monomer having a phosphoric acid ester group and a polyester resin having an unsaturated bond and a number average molecular weight of 3,000 or less.

Active energy ray curing composition, comprising a polymerizable monomer and a polyester resin

Provided is an active-energy-ray-curable ink including at least a surface tension modifier and including a monomer having a surface tension of 39 mN/m or greater in an amount of 20% by mass or greater but 60% by mass or less. Preferably, the ink includes a monomer having a surface tension of 43 mN/m or greater in an amount of 5% by mass or greater but 10% by mass or less.

Ink, ink set, ink container, recording method, and recording apparatus

The present invention addresses the novel problem of protecting against threats that can arise as a result of the development of networked or intelligent control devices and control systems. This controller system includes: a control unit that executes a control operation for controlling a control target; and a security unit that is connected to the control unit and oversees and manages security functions for the controller system. The security unit includes a detection means that detects whether any unauthorized intrusion into the controller system has occurred. The control unit includes a command transmission means that transmits commands for changing the behavior of the detection means of the security unit.

Controller system

To provide an appropriate method of treatment with pemafibrate for a liver cirrhosis patient. The present invention relates to the use of pemafibrate in a liver cirrhosis patient. More particularly, the present invention relates to a regimen for administering a reduced dose of pemafibrate to a liver cirrhosis patient in need of treatment with pemafibrate than to persons with normal liver function.

Medicament containing pemafibrate

A curable composition contains a polymerizable compound and a polymerization initiator containing pheylbis(2,4,6-trimethyl benzoyl)phosphine oxide and diphenyl(2,4,6-trimethylbenzoyl)phosphine oxide in a mass ratio of pheylbis(2,4,6-trimethyl benzoyl)phosphine oxide:diphenyl(2,4,6-trimethylbenzoyl)phosphine oxide from 1:6 to 1:160, wherein supernatant obtained after the curable composition is centrifuged for 30 minutes at 70,000 rotation per minute has an absorbance of 0.02 or less at a wavelength of 700 nm.

Curable composition, accommodating unit, device for forming two or three dimensional image, method of forming two or three dimensional image, and cured matter

A curable composition contains a polymerizable compound, a polymerization initiator, and a fluorescent whitener comprising a benzoxazole derivative, wherein the proportion of the fluorescent whitener is from 0.10 to 0.3 percent by mass and the proportion of the polymerization initiator is from 5 to 15 percent by mass.

A curable clear ink composition is provided. The curable clear ink composition comprises a surfactant, a monofunctional polymerizable compound having a static surface tension of 33 mN/m or less at 25 degrees C. in an amount of 10% by mass or more but 30% by mass or less, an oligomer having a weight average molecular weight (Mw) of 1,000 or more, and an acylphosphine oxide polymerization initiator in an amount of 8% by mass or more but 12% by mass or less.

Curable clear ink composition, storing container, ink set, printing method, printed matter, and cured material

An active energy ray-curable composition is provided. The active energy ray-curable composition comprises a polymerizable compound and a polymerization initiator. The polymerizable compound comprises isobornyl acrylate. The active energy ray-curable composition gives, when centrifuged with a centrifugal force of 8&#xd7;10g, a supernatant with an absorbance at a wavelength of 700 nm of 0.02 or lower.

Active energy ray-curable composition, active energy ray-curable inkjet ink, composition storage container, inkjet discharging apparatus, and cured product

A toner including polyester, wherein an amount of heat of a peak derived from the polyester in a range of from 40&#xb0; C. through 70&#xb0; C. during a cooling process is from 1.0 J/g through 15 J/g in differential scanning calorimetry performed under conditions below, &#x3c;measuring conditions&#x3e; after maintaining the toner at &#x2212;20&#xb0; C., heating the toner to 130&#xb0; C. at 10&#xb0; C./min (a first heating process), after maintaining the toner at 130&#xb0; C. for 1 minute, cooling the toner to &#x2212;50&#xb0; C. at cooling speed of 10&#xb0; C./min (the cooling process), and after maintaining the toner at &#x2212;50&#xb0; C. for 5 minutes, heating the toner to 130&#xb0; C. at 10&#xb0; C./min (a second heating process).

Toner, toner stored unit, image forming apparatus, and image forming method

An ink includes water, a coloring material, an organic solvent having a solubility parameter of from 8.0 to 13.0, an urethane resin particle and a metal ion, wherein the organic solvent having the solubility parameter of from 8.0 to 13.0 has a proportion of from 10.0% by mass to 30.0% by mass to the ink, where the metal ion is at least one selected from an alkali metal ion and an alkaline earth metal ion, where the metal ion has a proportion of from 4000 mg/L to 8000 mg/L to the ink.

Ink, ink container, recording device, recording set and recording method

Provided is a toner including toner base particles and an external additive, wherein each of the toner base particles includes a binder resin, a release agent, and silica, an average abundance ratio (X) of the silica on a region adjacent to a surface of the toner base particle is from 70% through 90%, and a projected area average value S(180) per particle of the toner when the toner is heated to 180&#xb0; C. and a projected area average value S(30) per particle of the toner when the toner is 30&#xb0; C. satisfy Formula (1) below,1.4&#x2264;(180)/(30)&#x2264;1.7&#x2003;&#x2003;Formula (1).

Toner, toner stored unit, and image forming apparatus

The present invention relates to a pharmaceutical composition for the treatment of primary biliary cirrhosis (PBC), in which containing a therapeutically effective amount of (R)-2-[3-[[N-(benzoxazol-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy] butyric acid, a salt thereof, or a solvate thereof.

Agent for treatment of PBC

Provided is a toner including at least: a binder resin; and a release agent, wherein in a transmission electron microscopic (TEM) image of a torn cross-section of the toner, the release agent has an acicular or filiform shape and an average aspect ratio of 31 or greater, and wherein a displacement amount of the toner when 250 micronewtons is applied to the toner in a microcompression test is 700 nm or less.

A toner includes a toner base particle including a binder resin; a release agent; and an inorganic fine particle, and an external additive. The inorganic fine particle is silica having an average abundance ratio at the surface of the toner base particle of from 70% to 90%. The toner base particle has a BET specific surface area of from 1.0 m/g to 2.5 m/g after the external additive is removed from the toner.

Toner, toner housing unit, and image forming apparatus

An electrostatic-image developing toner including at least a binder resin; a colorant; and a release agent, wherein an average circularity of particles having a particle diameter in a range of 0.79 times or more but less than 1.15 times as large as a most frequent diameter in a number particle size distribution of the toner is within a range of 1.010 times or more but less than 1.020 times as high as an average circularity of particles having a particle diameter of 1.15 times or more as large as the most frequent diameter.

Toner

Growing community of inventors

Shizuoka, Japan

Satoshi Kojima